Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes

Author(s): Clarence Hale and Minghan Wang

Volume 8 , Issue 7 , 2008

Page: [702 - 710] Pages: 9

DOI: 10.2174/138955708784567421

Price: $65

Abstract

Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11β-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.

Keywords: 11β-hydroxysteroid dehydrogenase, glucocorticoid receptor, cortisol, ex vivo activity, insulin resistance, Cushing's syndrome


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy